These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Novel combination of anionic and cationic polymethacrylate polymers for sustained release tablet preparation. Obeidat WM; Abu Znait AH; Sallam AS Drug Dev Ind Pharm; 2008 Jun; 34(6):650-60. PubMed ID: 18568916 [TBL] [Abstract][Full Text] [Related]
3. Novel Salted Anionic-Cationic Polymethacrylate Polymer Blends for Sustained Release of Acidic and Basic Drugs. Obeidat WM; Qasim D; Nokhodchi A; Al-Jabery A; Sallam AS Curr Drug Deliv; 2017; 14(1):109-122. PubMed ID: 27138298 [TBL] [Abstract][Full Text] [Related]
4. A novel pH-responsive interpolyelectrolyte hydrogel complex for the oral delivery of levodopa. Part II: characterization and formulation of an IPEC-based tablet matrix. Ngwuluka NC; Choonara YE; Kumar P; du Toit LC; Khan RA; Pillay V J Biomed Mater Res A; 2015 Mar; 103(3):1085-94. PubMed ID: 24909309 [TBL] [Abstract][Full Text] [Related]
5. Characteristics of interpolyelectrolyte complexes of Eudragit E100 with Eudragit L100. Moustafine RI; Kabanova TV; Kemenova VA; Van den Mooter G J Control Release; 2005 Mar; 103(1):191-8. PubMed ID: 15710510 [TBL] [Abstract][Full Text] [Related]
6. Floating and sustained-release characteristics of effervescent tablets prepared with a mixed matrix of Eudragit L-100-55 and Eudragit E PO. Bani-Jaber AK; Alkawareek MY; Al-Gousous JJ; Abu Helwa AY Chem Pharm Bull (Tokyo); 2011; 59(2):155-60. PubMed ID: 21297292 [TBL] [Abstract][Full Text] [Related]
7. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55. Sauer D; Zheng W; Coots LB; McGinity JW Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929 [TBL] [Abstract][Full Text] [Related]
8. Physicochemical characterization and drug release properties of Eudragit E PO/Eudragit L 100-55 interpolyelectrolyte complexes. Moustafine RI; Zaharov IM; Kemenova VA Eur J Pharm Biopharm; 2006 May; 63(1):26-36. PubMed ID: 16380241 [TBL] [Abstract][Full Text] [Related]
9. Assessment of Once Daily Controlled-release Ibuprofen Matrix Tablets Prepared using Eudragit Obeidat WM; Al-Natour MA Curr Drug Deliv; 2022; 19(1):74-85. PubMed ID: 34176461 [TBL] [Abstract][Full Text] [Related]
10. Multi-kinetic release of benznidazole-loaded multiparticulate drug delivery systems based on polymethacrylate interpolyelectrolyte complexes. García MC; Martinelli M; Ponce NE; Sanmarco LM; Aoki MP; Manzo RH; Jimenez-Kairuz AF Eur J Pharm Sci; 2018 Jul; 120():107-122. PubMed ID: 29705213 [TBL] [Abstract][Full Text] [Related]
11. Eudragit(®) RS PO/RL PO as rate-controlling matrix-formers via roller compaction: Influence of formulation and process variables on functional attributes of granules and tablets. Dave VS; Fahmy RM; Bensley D; Hoag SW Drug Dev Ind Pharm; 2012 Oct; 38(10):1240-53. PubMed ID: 22257339 [TBL] [Abstract][Full Text] [Related]
12. The effect of tablet formulation and hardness on in vitro release of cephalexin from Eudragit L100 based extended release tablets. Saravanan M; Nataraj KS; Ganesh KS Biol Pharm Bull; 2002 Apr; 25(4):541-5. PubMed ID: 11995942 [TBL] [Abstract][Full Text] [Related]
13. Permeability and swelling studies on free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery. Akhgari A; Farahmand F; Afrasiabi Garekani H; Sadeghi F; Vandamme TF Eur J Pharm Sci; 2006 Jul; 28(4):307-14. PubMed ID: 16713201 [TBL] [Abstract][Full Text] [Related]
14. Structural modifications of polymethacrylates: impact on thermal behavior and release characteristics of glassy solid solutions. Claeys B; De Coen R; De Geest BG; de la Rosa VR; Hoogenboom R; Carleer R; Adriaensens P; Remon JP; Vervaet C Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1206-14. PubMed ID: 23485474 [TBL] [Abstract][Full Text] [Related]
15. A Co-blended Locust Bean Gum and Polymethacrylate-NaCMC Matrix to Achieve Zero-Order Release via Hydro-Erosive Modulation. Ngwuluka NC; Choonara YE; Kumar P; du Toit LC; Modi G; Pillay V AAPS PharmSciTech; 2015 Dec; 16(6):1377-89. PubMed ID: 25956484 [TBL] [Abstract][Full Text] [Related]
16. Preparation and Evaluation of Ternary Polymeric Blends for Controlled Release Matrices Containing Weakly Basic Model Drug. Obeidat WM; Gharaibeh SF; Jaradat AA; Abualsuod O Curr Drug Deliv; 2021; 18(1):54-64. PubMed ID: 32735522 [TBL] [Abstract][Full Text] [Related]
17. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436 [TBL] [Abstract][Full Text] [Related]
18. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Ibekwe VC; Fadda HM; Parsons GE; Basit AW Int J Pharm; 2006 Feb; 308(1-2):52-60. PubMed ID: 16356670 [TBL] [Abstract][Full Text] [Related]
19. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers. Zhu Y; Shah NH; Malick AW; Infeld MH; McGinity JW Drug Dev Ind Pharm; 2006 Jun; 32(5):569-83. PubMed ID: 16720412 [TBL] [Abstract][Full Text] [Related]
20. (Meth)acrylate copolymers of Eudragit® type in oral tablet technology. Naiserová M; Kubová K; Vysloužil J; Bernatoniene J; Brokalakis I; Vetchý D Ceska Slov Farm; 2019; 68(5):183-197. PubMed ID: 31896262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]